Effect of Tołpa Peat Preparation on some immune parameters in healthy volunteers. Preliminary data.
Investigations of some immune parameters were carried out in healthy humans receiving TPP in doses of 50, 100, 300 and 600 mg daily for 14 days. The percent and composition of T lymphocyte subsets were studied along with the ability to generate interleukin-1 (Il-1) and interleukin-2 (Il-2) as well as spontaneous and PHA stimulated expression of receptors for Il-2 (TAC) and transferrin receptor (Tr) on lymphocytes. Lymphocytes proliferation induced with mitogens and alloantigens, generation of both Tumour Necrosis Factor alpha(TNF alpha) by monocytes and superoxide radicals by granulocytes were estimated. A 50 mg dose of TPP changed neither the T-cell percent among mononuclear cells nor the composition of T-cell subsets. A higher dosage of 100 mg of TPP caused a significant increase of the percent of T-cells on the 14th day but did not influence their subset composition. On the 14th and 28th day of the observation a statistically insignificant decrease of IL-2 generation was observed but with no change of both TAC receptor expression on lymphocytes and the ability to generate IL-1 by monocytes. TPP in the doses of 50 and 100 mg exerted a slight immunomodulatory potential in healthy humans, however the immunological parameters assessed were within the standard values. In other immune parameters examined during the administration of higher TPP doses in human groups consisted of four volunteers considerable differences have been found but individual differences in a limited experimental group and the lack of a placebo group did not allow for definite conclusions but for preliminary data only.
Baj
Z
Z
Department of Pathophysiology and Immunology, Institute of Basic Medical Sciences, WAM, Lódź, Poland.
Zeman
K
K
Sułowska
Z
Z
Majewska
E
E
Pokoca
L
L
Kocur
E
E
Kantorski
J
J
Fornalczyk
E
E
Banasik
M
M
Tchórzewski
H
H
D000328:Adult; D000596:Amino Acids / Q000494:pharmacology*; D002241:Carbohydrates / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis*; D004338:Drug Combinations; D006801:Humans; D006812:Humic Substances / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D008297:Male; D015375:Receptors, Interleukin-2 / Q000187:drug effects; D011990:Receptors, Transferrin / Q000187:drug effects; D012987:Soil; D014574:Uronic Acids / Q000494:pharmacology*
D000596:Amino Acids; D002241:Carbohydrates; D016207:Cytokines; D004338:Drug Combinations; D006812:Humic Substances; D015375:Receptors, Interleukin-2; D011990:Receptors, Transferrin; D012987:Soil; C084029:Tolpa; D014574:Uronic Acids